Clinical trial
Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture
NCT00317213 · Kaplan Medical Center, Other · Completed
Key facts
| NCT number | NCT00317213 |
|---|---|
| Title | Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture |
| Official title | Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation |
| Lead sponsor | Kaplan Medical Center, Other |
| Collaborators | Modus Biological Membranes, Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking |
| Intervention type | Drug |
| Interventions | LIBERTAL- a phospholipid mixture |
| Enrollment | 500 |
| Start date | Feb 1, 2002 |
| Completion | Jul 1, 2002 |
| First posted | Apr 24, 2006 |
| Last update posted | Apr 14, 2008 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: